Indivior Pharmaceuticals, Inc. Cost of Revenue
Indivior Pharmaceuticals, Inc. (INDV) reported Cost of Revenue of $50.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $50.00M, a 3.85% decline year-over-year.
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $40.00M, a 9.09% decline year-over-year.
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $67.00M, a 39.58% increase year-over-year.
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $83.00M, a 25.76% increase year-over-year.
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2025 was $246.00M, a 6.49% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2024 was $231.00M, a 32.76% increase from fiscal 2023.
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2023 was $174.00M, a 15.23% increase from fiscal 2022.
- Indivior Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2022 was $151.00M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.00M 10-Q · filed 2026-08-03 | $90.00M 10-Q · filed 2026-08-03 | $157.00M derived: sum of 3 quarters · filed 2026-08-03 | $240.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $40.00M 10-Q · filed 2026-04-30 | $107.00M derived: sum of 2 quarters · filed 2026-04-30 | $190.00M derived: sum of 3 quarters · filed 2026-04-30 | $242.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $67.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $150.00M derived: sum of 2 quarters · filed 2026-02-26 | $202.00M derived: sum of 3 quarters · filed 2026-08-03 | $246.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $83.00M 10-Q · filed 2025-10-30 | $135.00M derived: sum of 2 quarters · filed 2026-08-03 | $179.00M 10-Q · filed 2025-10-30 | $227.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $52.00M 10-Q · filed 2026-08-03 | $96.00M 10-Q · filed 2026-08-03 | $144.00M derived: sum of 3 quarters · filed 2026-08-03 | $210.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $44.00M 10-Q · filed 2026-04-30 | $92.00M derived: sum of 2 quarters · filed 2026-04-30 | $158.00M derived: sum of 3 quarters · filed 2026-04-30 | $237.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $114.00M derived: sum of 2 quarters · filed 2026-02-26 | $193.00M derived: sum of 3 quarters · filed 2026-02-26 | $231.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $66.00M 10-Q · filed 2025-10-30 | $145.00M derived: sum of 2 quarters · filed 2025-10-30 | $183.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $79.00M 10-Q · filed 2025-07-31 | $117.00M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $38.00M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $174.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $151.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |